Ghrelin and GH Secretagogue Receptors Found on Human Cancer Cells

Specific ghrelin and synthetic GH secretagogue binding sites were identified on human breast, prostate, and lung cancer cells, with functional activity suggesting the ghrelin system may influence cancer cell behavior.

Cassoni, P et al.·The Journal of clinical endocrinology and metabolism·2001·Preliminary Evidencein-vitro
RPEP-00654In VitroPreliminary Evidence2001RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Functional ghrelin and synthetic GHS receptors were identified on human breast, prostate, and lung cancer cells, with receptor subtypes potentially different from those in normal pituitary tissue.

Key Numbers

How They Did This

In-vitro binding study using radioligands on human cancer cell lines (breast, prostate, lung). Binding competition with ghrelin and synthetic GHS. Functional signaling assessed by second messenger assays.

Why This Research Matters

If cancer cells respond to ghrelin and GH secretagogues, this has dual implications: potential cancer therapeutic targets AND safety concerns for people using GH peptides.

The Bigger Picture

The ghrelin receptor system's presence on common cancers means it could either promote or inhibit tumor growth. This creates both a therapeutic opportunity and a safety question for the growing use of GH secretagogues.

What This Study Doesn't Tell Us

In-vitro cancer cell line study. Receptor presence doesn't determine whether activation promotes or inhibits cancer growth. Cell lines may not represent primary tumors.

Questions This Raises

  • ?Does ghrelin signaling promote or inhibit cancer cell growth?
  • ?Should GH secretagogue users be concerned about cancer risk?
  • ?Could ghrelin receptor-targeted drugs be developed for cancer therapy?

Trust & Context

Key Stat:
On 3 cancer types Functional ghrelin receptors found on breast, prostate, AND lung cancer cells — the three most common cancers
Evidence Grade:
Preliminary in-vitro evidence identifying functional receptors on cancer cells, raising important questions but not determining clinical significance.
Study Age:
Published in 2001. The ghrelin-cancer relationship has been further studied with mixed results — some studies showing growth promotion, others inhibition, depending on cancer type.
Original Title:
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.
Published In:
The Journal of clinical endocrinology and metabolism, 86(4), 1738-45 (2001)
Database ID:
RPEP-00654

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Do GH peptides affect cancer?

Cancer cells have ghrelin receptors, meaning GH secretagogues could potentially affect them. Whether this promotes or inhibits cancer isn't yet clear — research shows mixed results depending on cancer type.

Should people with cancer avoid GH peptides?

The clinical significance is uncertain. Until more is known, people with cancer or high cancer risk should discuss GH secretagogue use with their oncologist. The presence of receptors on cancer cells is concerning but not proof of harm.

Read More on RethinkPeptides

Cite This Study

RPEP-00654·https://rethinkpeptides.com/research/RPEP-00654

APA

Cassoni, P; Papotti, M; Ghè, C; Catapano, F; Sapino, A; Graziani, A; Deghenghi, R; Reissmann, T; Ghigo, E; Muccioli, G. (2001). Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.. The Journal of clinical endocrinology and metabolism, 86(4), 1738-45.

MLA

Cassoni, P, et al. "Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.." The Journal of clinical endocrinology and metabolism, 2001.

RethinkPeptides

RethinkPeptides Research Database. "Identification, characterization, and biological activity of..." RPEP-00654. Retrieved from https://rethinkpeptides.com/research/cassoni-2001-identification-characterization-and-biological

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.